Find a company by name or ticker and open its page
We use analytics cookies to understand how you use Stockoscope and improve the platform. Essential cookies that keep you logged in are always on. Cookie policy
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
PTCPRNewsWireWARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Jefferies Global Healthcare Conference Monday, Nov. 16 at 11 a.m.
Also in the news
Zacks Investment Research
GlobeNewsWire
GlobeNewsWire
PTCPRNewsWireWARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its common stock and 11,535 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 13 new employees.
PTCSeeking AlphaThe portfolio's outperformance was primarily driven by our holdings in the Health Care sector, which delivered strong returns for the quarter on company-specific catalysts. Information Technology holdings and underweight to the Energy sector detracted from returns. For the year-to-date period, the Fund returned 5.80% (net of fees), outperforming the Russell Midcap Growth Index's 1.01%.
PTCMarketBeatPTC Therapeutics NASDAQ: PTCT reported third-quarter 2026 total revenue of $358 million, including $276 million in net product revenue, as sales of phenylketonuria treatment Sephience continued to expand in the United States and internationally.
PTCPRNewsWire– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue guidance raised to $960 to $990 million – – Sephience™ (sepiapterin) Q3 2026 revenue of $182 million, with continued growth in the US and ongoing global expansion – – Acquired ST-920 Fabry disease gene therapy; BLA submission expected to be completed in Q4 2026 – WARREN, N.J., Oct. 29, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ended September 30, 2026.
PTCZacks Investment ResearchPTC Inc. (PTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTCGlobeNewsWireIn naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142) “Speedy,” a PTC-2105-treated mouse now more than 167 weeks old, has outlived every saline-treated negative control in his study by more than 20% and remains active day and night New “Team Speedy” webpage, launching today at eossenolytix.com/team-speedy, invites the public to watch Speedy, predict how far he will go, and sign up for milestone alerts BERLIN and HOUSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. (“Eos” or the “Company”) a biotechnology company developing mitochondria-targeted geropeptides to improve healthspan, today presented new preclinical survival, healthspan and mechanism-of-action data for its lead candidate, PTC-2105, in an Industry Keynote Address at the 17th World Congress on Targeting Mitochondria 2026 in Berlin. The keynote, “Building on the Foundation of Four: Advancing Mitochondrial-Targeted Geropeptide Medicine,” delivered by Dr. Kevin Slawin, Founder and CEO of Eos SENOLYTIX, acknowledged the contribution of Dr. Hazel Szeto, who with Dr. Peter Schiller co-discovered the four amino acid peptide, SS-31, (“elamipretide”), the first FDA-approved therapeutic that directly targets mitochondria.
PTCPRNewsWireBrings internal teams, suppliers, and partners into secure Rooms to review 2D and 3D product content in the browser Keeps comments, markups, versions, and decisions in context to accelerate reviews and reduce rework Leverages AI to turn complex discussions into clear and actionable next steps and Windchill connectivity to carry decisions into downstream execution BOSTON, Oct. 21, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the launch of its PTC Jetstream™ cloud and AI-native product collaboration solution to connect people, product information, and decisions – enabling product companies to move faster, catch issues earlier, and bring great products to market. As products become more complex, organizations need to bring expertise from across the business into the development process without slowing innovation, but reviews and discussions that shape a product are often scattered across disconnected tools and processes.
PTCPRNewsWireBOSTON, Oct. 19, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) will release its fiscal 2026 fourth quarter and full year results on Wednesday, November 4th after the stock market closes. As previously announced on October 5th, 2026, PTC entered into a definitive agreement to be acquired by Schneider Electric.
PTCPRNewsWireOptimizes service parts across complex global supply network Transforms planning productivity through exception-based management AI-powered intelligence built on deep service supply chain expertise and proven optimization science BOSTON, Oct. 15, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that the United States Air Force (USAF) has extended its use of PTC's Servigistics® service supply chain optimization solution as part of its Enterprise Supply Chain Analysis, Planning, and Execution (ESCAPE) program. The renewal extends a nearly decade-long relationship focused on modernizing the Air Force service supply chain and improving aircraft and system readiness.